Company highlights during the first half of 2017 include China approval for Novaprep for non-gynecological cancer testing, and a €3 million private financing round.
The clinical diagnostics company will use the funds to invest in a new UK-based manufacturing facility and to accelerate global growth.
Analyses of T cell therapy-responsive metastatic HPV-positive cervical cancers suggest the immune cells largely respond to tumor rather than viral antigens.
The contract includes a milestone of approval by the Chinese Food and Drug Agency within the next three years.
The test for cervical cancer screening previously received the IVD mark and US Food and Drug Administration approval on the Cobas 4800 system.
The test will be developed in Global Good labs and ported onto QuantuMDx's handheld molecular platform.
In Nature this week: Plasmodium genomes and evolution, novel developmental disorder loci, and more.
The Cancer Genome Atlas Research Network team uncovered new mutations and amplifications in their cohort of primary cervical cancers.
The firms will target 18 Latin American countries in three years, with the goal of creating a complete HPV diagnostics system for the region.
The firm is also pursuing ovarian cancer screening and head and neck cancer tests using methylation-specific PCR.
Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.
By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.
Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.
In Nature this week: a Danish reference genome, and more.